Spinal muscular atrophy is an autosomal-recessive, progressive neuromuscular disease associated with extensive morbidity. Children with spinal muscular atrophy have potentially increased life spans due to improved nutrition, respiratory support, and novel pharmaceuticals.
Objectives:
To report on the quality of life and family experience for children with spinal muscular atrophy with attentiveness to patient- and proxy-concordance and to stratify quality of life reports by spinal muscular atrophy type and medical interventions.
Methods:
A prospective, crossover survey study inclusive of 58 children (26 spinal muscular atrophy type I, 23 type II, 9 type III) and their family caregivers at a free-standing Midwestern children’s hospital. Twenty-eight families completed the 25-item PedsQL 3.0 Neuromuscular Module. Forty-four participants completed the 36-item PedsQL Family Impact Module and 47 completed the Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD) questionnaire.
Results:
The PedsQL Family Impact Module demonstrated significant differences between spinal muscular atrophy types I and II in functioning domains including physical, emotional, social, and family relations (P < .03). Child self-report and proxy report surveys demonstrated significant differences between spinal muscular atrophy types in the communication domains (P < .003). Children self-reported their quality of life higher than proxy report of child quality of life. Gastrostomy tube (P = .001) and ventilation support (P = .029) impacted proxy-reported quality of life perspectives, whereas nusinersen use did not. Spinal surgery was associated with improved parental quality of life and family impact (P < .03).
Conclusions:
The measurement and monitoring of quality of life for children with spinal muscular atrophy and their families represents an implementable priority for care teams.
PechmannAKirschnerJ. Diagnosis and new treatment avenues in spinal muscular atrophy. Neuropediatrics. 2017;48:273–281.
4.
KostovaFVWilliamsVCHeemskerkJ, et al.Spinal muscular atrophy: classification, diagnosis, management, pathogenesis, and future research directions. J Child Neurol. 2007;22:926–945.
5.
FinkelRSMercuriEMeyerOH, et al.Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197–207.
6.
MercuriEFinkelRSMuntoniF, et al.Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103–115.
7.
LemoineTJSwobodaKJBrattonSL, et al.Spinal muscular atrophy type 1: are proactive respiratory interventions associated with longer survival?Pediatr Crit Care Med. 2012;13:e161–e165.
8.
LovgrenMSejersenTKreicbergsU. Information and treatment decisions in severe spinal muscular atrophy: a parental follow-up. Eur J Paediatr Neurol. 2016;20:830–838.
9.
LovgrenMSejersenTKreicbergsU. Parents’ experiences and wishes at end of life in children with spinal muscular atrophy types I and II. J Pediatr. 2016;175:201–205.
10.
ArnoldWDKassarDKisselJT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51:157–167.
11.
TisdaleSPellizzoniL. Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J Neurosci. 2015;35:8691–8700.
12.
TalbotKTizzanoEF. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017;24:529–533.
13.
GroenEJNTalbotKGillingwaterTH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14:214–224.
14.
AbreschRTCarterGTJensenMP, et al.Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease. Am J Hosp Palliat Care. 2002;19:39–48.
15.
KhannaDTsevatJ. Health-related quality of life—an introduction. Am J Manag Care. 2007;13(suppl 9):S218–S223.
16.
What quality of life? The WHOQOL group. World health organization quality of life assessment. World Health Forum. 1996;17:354–356.
17.
IannacconeSTHynanLSMortonA, et al.The PedsQL in pediatric patients with spinal muscular atrophy: feasibility, reliability, and validity of the pediatric quality of life inventory generic core scales and neuromuscular module. Neuromuscul Disord. 2009;19:805–812.
18.
KlugCSchreiber-KatzOThieleS, et al.Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11:58.
19.
KocovaHDvorackovaOVondracekP, et al.Health-related quality of life in children and adolescents with spinal muscular atrophy in the Czech Republic. Pediatr Neurol. 2014;50:591–594.
20.
VarniJWShermanSABurwinkleTM, et al.The PedsQL family impact module: preliminary reliability and validity. Health Qual Life Outcomes. 2004;2:55.
21.
NarayananUGFehlingsDWeirS, et al.Initial development and validation of the Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD). Dev Med Child Neurol. 2006;48:804–812.
22.
BenjaminiYHochbergY. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B1995;57:289–300.
23.
HolmS. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70.
24.
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2018.
25.
Iannaccone ST, Hynan LS. American Spinal Muscular Atrophy Randomized Trials (amSMART) Group. Reliability of 4 outcome measures in pediatric spinal muscular atrophy. Arch Neurol. 2003;60:1130–1136.
26.
VaidyaSBoesS. Measuring quality of life in children with spinal muscular atrophy: a systematic literature review. Qual Life Res. 2018;27:3087–3094.
27.
BertiniEDessaudEMercuriE, et al.Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:513–522.
28.
KisselJTScottCBReynaSP, et al.SMA Carnival Trial Part II: a prospective, single-armed trial of l-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One. 2011;6:e21296.
29.
ChiribogaCASwobodaKJDarrasBT, et al.Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890–897.
30.
GonzalezRBustinzaAFernandezSN, et al.Quality of life in home-ventilated children and their families. Eur J Pediatr. 2017;176:1307–1317.
31.
PembertonJFrankfurterCBaileyK, et al.Gastrostomy matters—the impact of pediatric surgery on caregiver quality of life. J Pediatr Surg. 2013;48:963–970.
32.
ChanYHLimCZBautistaD, et al.The health and well-being of caregivers of technologically dependent children. Global Pediatr Health. 2019;6:2333794X18823000.
33.
QianYMcGrawSHenneJ, et al.Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents: a qualitative study. BMC Neurol. 2015;15:217.
34.
BeernaertKLovgrenMJeppesenJ, et al.Parents’ experiences of information and decision making in the care of their child with severe spinal muscular atrophy: a population survey. J Child Neurol. 2019;34:210–215. doi:10.1177/0883073818822900.
35.
HjorthEKreicbergsUSejersenT, et al.Parents’ advice to healthcare professionals working with children who have spinal muscular atrophy. Eur J Paediatr Neurol. 2018;22:128–134.
36.
HjorthEKreicbergsUSejersenT, et al.Bereaved parents more satisfied with the care given to their child with severe spinal muscular atrophy than nonbereaved. J Child Neurol. 2019;34:104–112.
37.
Eiser CMorseR. Can parents rate their child’s health-related quality of life? Results of a systematic review. Qual Life Res. 2001;10:347–357.
38.
White-KoningMArnaudCDickinsonHO, et al.Determinants of child-parent agreement in quality-of-life reports: a European study of children with cerebral palsy. Pediatrics. 2007;120:e804–e814.
39.
DavisENicolasCWatersE, et al.Parent-proxy and child self-reported health-related quality of life: using qualitative methods to explain the discordance. Qual Life Res. 2007;16:863–871.
40.
MandrellBNBakerJLevineD, et al.Children with minimal chance for cure: parent proxy of the child’s health-related quality of life and the effect on parental physical and mental health during treatment. J Neurooncol. 2016;129:373–381.
41.
TheunissenNCVogelsTGKoopmanHM, et al.The proxy problem: child report versus parent report in health-related quality of life research. Qual Life Res. 1998;7:387–397.
42.
VarniJWLimbersCABurwinkleTM. How young can children reliably and validly self-report their health-related quality of life? An analysis of 8,591 children across age subgroups with the PedsQL 4.0 generic core scales. Health Qual Life Outcomes. 2007;5:1.
43.
McGrawSQianYHenneJ, et al.A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 2017;17:68.
44.
JardineJGlinianaiaSVMcConachieH, et al.Self-reported quality of life of young children with conditions from early infancy: a systematic review. Pediatrics. 2014;134:e1129–e1148.
45.
WeaverMSDarnallCBaceS, et al.Trending longitudinal agreement between parent and child perceptions of quality of life for pediatric palliative care patients. Children (Basel). 2017;4.
46.
VarniJWBurwinkleTMLaneMM. Health-related quality of life measurement in pediatric clinical practice: an appraisal and precept for future research and application. Health Qual Life Outcomes. 2005;3:34.
47.
RyanJLMellonMWJungerKW, et al.The clinical utility of health-related quality of life screening in a pediatric inflammatory bowel disease clinic. Inflamm Bowel Dis. 2013;19:2666–2672.
48.
UzarkKKingESpicerR, et al.The clinical utility of health-related quality of life assessment in pediatric cardiology outpatient practice. Congenit Heart Dis. 2013;8:211–218.
